Microdosing Semaglutide Split-dosing protocols for improved tolerability
A huge shoutout to Tracy, she is absolutely amazing and made me feel so comfortable throughout my visit
10.1016/j.cyto.2007.11.022 22 KolloliA.KumarR.SinghP.NarangA.KaplanG.SigalA.et al (2021)
GLP-1 receptor agonists are shifting healthcare from: glucose control to whole-body metabolic disease modification. The future of endocrinology will likely be built around: precision metabolic medicine, multi-agonist therapies, oral incretin platforms, and integrated cardiometabolic care
They are FDA-approved and have been shown to be safe and effective
Dose: 0.51 mg per day , subcutaneous Frequency: 35 times weekly Cycle: 8 weeks on / 4 weeks off , repeated indefinitely Stack: commonly run alongside NAD+ infusions and CJC-1295 / Ipamorelin for full anti-ageing coverage